8-KLeadership ChangesExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (Oct 25, 2007)

Filed October 25, 2007For Securities:DXCM

Summary

This Form 8-K filing by DexCom, Inc. (DXCM) on October 25, 2007, primarily details changes to executive compensation and severance arrangements, specifically focusing on the CEO, Terrance H. Gregg, and other key executives. The most significant information for investors pertains to the amended employment terms for the CEO, which include an additional stock option grant and a performance-based bonus tied to the company's stock performance. Additionally, the company has established a standardized "Change of Control & Severance Agreement" for its named executive officers and other senior personnel, outlining benefits in the event of a change in company control or termination without cause. These agreements reflect an effort to retain and incentivize key leadership during a period that may involve significant corporate events. Investors should note the potential dilution from the additional stock options and the financial implications of the severance and change-in-control provisions, which could impact shareholder value depending on future corporate actions and executive departures. The details provided offer insight into the company's strategy for executive compensation and its preparedness for potential transitional events.

Key Highlights

  • 1DexCom, Inc. (DXCM) filed an 8-K on October 25, 2007, reporting on executive compensation and severance agreements.
  • 2Terrance H. Gregg, CEO, received an amended offer letter, including an additional stock option grant of 393,000 shares and a performance-based bonus.
  • 3The additional stock option for the CEO will be granted on January 2, 2008, with an exercise price based on the closing price on that date.
  • 4The CEO's bonus is contingent on the positive difference between the stock price on the grant date and the initial employment date, multiplied by the option shares.
  • 5A "Change of Control & Severance Agreement" was approved for named executive officers and other senior executives.
  • 6This agreement provides for full acceleration of stock option vesting in the event of a change of control or constructive termination.
  • 7In cases of termination without cause or constructive termination, executives will receive 12 months' salary as severance and 12 months of vesting acceleration, subject to signing a release.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce and provide details on amendments to the employment agreement for DexCom's CEO, Terrance H. Gregg, including additional stock options and bonus arrangements, as well as the adoption of a standard Change of Control & Severance Agreement for other key executives.

The amended offer letter includes an additional stock option grant of 393,000 shares for the CEO. If exercised, this will result in the issuance of new shares, potentially leading to dilution for existing shareholders. The exact impact will depend on the exercise price and the timing of exercise.

Under the Change of Control & Severance Agreement, executives are entitled to accelerated vesting of all stock options and awards in the event of a change of control or if terminated without cause or due to constructive termination within a specified period around a change of control. In cases of termination without cause or constructive termination, executives also receive 12 months of salary as severance pay.

The additional stock option is scheduled to be granted on January 2, 2008. The bonus will be calculated based on the stock price on that grant date and the original employment date and will be paid in installments as the option vests. The company has the option to pay the bonus in cash or company stock.